Cell
“Armed” oncolytic herpes simplex virus enables CD19/BCMA CAR-T for solid tumor treatment as a combination therapy
12 Oct
16:50
-
17:30
Speakers
About the Session
- oHSV MVR-T7 series was genetically engineered to drive ectopic expression of the extracellular domain of CD19/BCMA.
- Co-culture studies were performed to test the cell-killing activity of CD19/BCMA CAR-T combined with T7.
- Antitumor activities of T7011 administrated via intratumoral (IT) or intraperitoneal (IP) in combination with CD19 CAR-T cells were assessed in immunodeficient and immunocompetent mice.
